European Journal of Radiology Open (Jun 2024)
Deep learning radiomics model based on PET/CT predicts PD-L1 expression in non-small cell lung cancer
Abstract
Purpose: Programmed cell death protein-1 ligand (PD-L1) is an important prognostic predictor for immunotherapy of non-small cell lung cancer (NSCLC). This study aimed to develop a non-invasive deep learning and radiomics model based on positron emission tomography and computed tomography (PET/CT) to predict PD-L1 expression in NSCLC. Methods: A total of 136 patients with NSCLC between January 2021 and September 2022 were enrolled in this study. The patients were randomly divided into the training dataset and the validation dataset in a ratio of 7:3. Radiomics feature and deep learning feature were extracted from their PET/CT images. The Mann-whitney U-test, Least Absolute Shrinkage and Selection Operator algorithm and Spearman correlation analysis were used to select the top significant features. Then we developed a radiomics model, a deep learning model, and a fusion model based on the selected features. The performance of three models were compared by the area under the curve (AUC), sensitivity, specificity, accuracy, positive predictive value, and negative predictive value. Results: Of the patients, 42 patients were PD-L1 negative and 94 patients were PD-L1 positive. A total of 2446 radiomics features and 4096 deep learning features were extracted per patient. In the training dataset, the fusion model achieved a highest AUC (0.954, 95% confident internal [CI]: 0.890–0.986) compared with the radiomics model (0.829, 95%CI: 0.738–0.898) and the deep learning model (0.935, 95%CI: 0.865–0.975). In the validation dataset, the AUC of the fusion model (0.910, 95% CI: 0.779–0.977) was also higher than that of the radiomics model (0.785, 95% CI: 0.628–0.897) and the deep learning model (0.867, 95% CI: 0.724–0.952). Conclusion: The PET/CT-based deep learning radiomics model can predict the PD-L1 expression accurately in NSCLC patients, and provides a non-invasive tool for clinicians to select positive PD-L1 patients.
